Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

La Jolla Pharmaceutical Co.

www.ljpc.com

Latest From La Jolla Pharmaceutical Co.

Amgen/UCB To Appeal EMA’s 'Over Cautious' Evenity Rejection

Amgen and UCB say that the European Medicines Agency’s re-examination process should allow them to clarify their position on the data supporting the marketing authorization application for their osteoporosis drug, Evenity. Meanwhile, three other drugs received a positive opinion from the EMA this week for pan-EU approval, including La Jolla’s Giapreza.
Europe Approvals

Romosozumab Among Latest Drugs Up For CHMP Opinion

Four drugs are up for an opinion this week on whether they should be granted EU-wide approval, including Amgen/UCB's osteoporosis drug romosozumab.
Europe Approvals

Companies Keep The Faith As New Products Await EMA Verdict

Mitsubishi and Emmaus Life Sciences are among the companies that will find out this week whether the European Medicines Agency's drug evaluation committee, the CHMP, will recommend their new products for EU approval.

Europe Approvals

Celgene, Agios Drug Enasidenib Among New Filings At EMA

Enasidenib, which last year became the first US-approved treatment for relapsed or refractory acute myeloid leukemia with an IDH2 mutation, is among a new crop of products being reviewed for marketing approval in the EU.

Drug Review Review Pathway
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cardiovascular
  • Hepatic (Liver)
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • La Jolla Pharmaceutical Co.
  • Senior Management
  • George F Tidmarsh, MD, PhD, Pres. & CEO
    Dennis Mulroy, CFO
    James M Rolke, CSO
    Lakmir S Chawla, MD, CMO
    Jennifer A Carver, MBA, COO
  • Contact Info
  • La Jolla Pharmaceutical Co.
    Phone: (858) 207-4264
    4550 Towne Centre Ct.
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register